CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 150 enrolled
Drug / intervention
Medtronic TAVR Systemsdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03635424
NCT03635424N/AActive

Transcatheter Aortic Valve Replacement (TAVR) With Medtronic TAVR System in Patients With Severe Bicuspid Aortic Valve Stenosis and at Low Predicted Risk of Mortality With Surgical Aortic Valve Replacement (SAVR)

Medtronic Cardiovascular·interventional·Posted Aug 17, 2018·Updated May 5, 2026

In Brief

A clinical study evaluating Medtronic TAVR Systems for Bicuspid Aortic Valve. Active but no longer recruiting, targeting 150 participants across 25 sites.

Detailed Summary

The objective of the trial is to evaluate the procedural safety and efficacy of the Medtronic TAVR system in patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/AActive
2019202020212022202320242025202620272028202920302031
First PostedAug 17, 2018
Enrollment StartOct 30, 2018
Primary CompletionNov 13, 2019
Study CompletionDec 1, 2030
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.9 years ago

Interventions

Medtronic TAVR Systemsdevice

Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems